Ticker Symbol: RZLT
Rezolute Inc
$6.00 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001509261
Company Profile
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric endocrine disorder. Its pipeline also includes RZ402, an IND-ready orally available plasma kallikrein inhibitor, which is staged to transition into clinical development for the treatment of diabetic macular edema.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 201 Redwood Shores Pkwy Ste 315
Website: www.rezolutebio.com
CEO: Nevan Elam
Tags:
- Internet Software/Services
- Technology Services
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.22
Change:
-$0.02
(
-1.61%)
Days Range: $1.21 - $1.29
Beta: 0.83
52wk. High: $2.90
52wk. Low: $0.81
Ytd. Change -41.71%
50 Day Moving Average: $1.27
200 Day Moving Average: $1.76
Shares Outstanding: 36827567
Valuation
Market Cap: 4.5B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A